At week 4 of the trial , 19 ( 76 % ) of the 25 venlafaxine + bright light therapy patients versus just 11 ( 44 % ) of the 25 venlafaxine patients ( P < .05 ) attained the target goal of treatment , a HDRS score 13 , indicative of mild depression , and , although not statistically significant in our small sample study ( P = .36 ) , at week 8 , 76 % of venlafaxine + bright light therapy patients ( n = 19 ) versus just 64 % of the venlafaxine patients ( n = 16 ) experienced complete remission of depression ( HDRS score 7 ) .